A synbiotic marine oligosaccharide microcapsules for enhancing Bifidobacterium longum survivability and regulatory on intestinal probiotics

A novel synbiotic multiparticulate microparticle containing alginate oligosaccharide (AOS), chitosan oligosaccharide (COS) andBifidobacterium longumCICC 6259 was produced in the current study to expand the synbiotic industrial applications. The influences of these treatments on encapsulation yield, size, morphology, protective effect and stability of microcapsules and on mice gut microbiome were studiedin vitroandin vivo.In vitroexperiments detected no significant difference (P > 0.05) in encapsulation yield with different types of microcapsules. However, the microcapsule diameter of marine oligosaccharide was approximately 60 mu m greater, and these microcapsules increased the number of surviving cells by more than 3 log cfu/g after treatment with simulated gastrointestinal juices, compared to basic alginate microcapsules.In vivo, these microcapsules significantly increased the content ofBifidobacteriumandLactobacillusand reduced the content ofEnterococcusandEscherichiain mice gut microbiome. Marine oligosaccharide probiotic microcapsules are promising as a novel functional food ingredient.

Automated summary

A novel synbiotic multiparticulate microparticle containing alginate oligosaccharide, chitosan oligosaccharide, and Bifidobacterium longum CICC 6259 was developed in this study for potential industrial applications. In vitro experiments showed that marine oligosaccharide microcapsules had a larger diameter and increased survival of cells after exposure to simulated gastrointestinal juices compared to basic alginate microcapsules. In vivo studies demonstrated that these microcapsules significantly altered the gut microbiome in mice by increasing the content of Bifidobacterium and Lactobacillus and reducing the content of Enterococcus and Escherichia.